This report provides an overview of global clinical trials with a start date between January 1, 2023, and December 31, 2023.
Scope
The clinical trials data used for these analyses were extracted from the analyst’s Clinical Trials Database. The data includes clinical trials with a start date between January 1, 2023 and December 31, 2023, which were captured in the database as of February 14, 2023. The trials were analyzed and segmented by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, molecule type, and top drug trials.Reasons to Buy
Trends of 2023 trial landscape
Comparison to 2022 trial landscape
Can view top therapy areas, indications, geographies and sponsors for 2023 trials
Designated focus on completed and terminated trials for 2023Table of Contents
- Executive Summary
- Introduction
- Global Clinical Trial Landscape in 2023
- Completed Trials in 2023
- Clinical Trial Terminations in 2023
- Key Findings
- Appendix
- Figure 1 and 2: Clinical trials by sponsor type, status and initiation/completion
- Figure 3 and 4: Clinical trials, by phase and sponsor type
- Figure 5: Single country and multinational trials
- Figure 6: Clinical trials regions, by phase
- Figure 7: Clinical trials regions, by phase and distribution
- Figure 8: Clinical trials in top countries, by phase
- Figure 9: Clinical trials in top countries, by phase and distribution
- Figure 10: Clinical trials top therapy areas, by phase
- Figure 11: Clinical trials top therapy areas, by phase and distribution
- Figure 12: Pivotal/registration clinical trials top therapy areas, by phase
- Figure 13: Clinical trials top indications, by phase
- Figure 14: Clinical trials top indications, by phase and distribution
- Figure 15: Pivotal/registration clinical trials top indications, by phase
- Figure 16: Clinical trials top industry sponsors, by phase
- Figure 17: Clinical trials top non-industry sponsors, by phase
- Figure 18: Pivotal/registration clinical trials top industry sponsors, by phase
- Figure 19: Completed trials endpoint status, by sponsor type
- Figure 20 and 21: Completed trials endpoint status, by sponsor type and phase
- Figure 22: Pivotal/registration industry-sponsored trials endpoint status, by phase
- Figure 23: Completed clinical trials top sponsors, by phase
- Figure 24: Top completed drugs, by clinical trial count
- Figure 25 and 26: Terminated trials, by phase and reason
- Figure 27: Terminated clinical trials top therapy areas, by phase
- Figure 28: Terminated clinical trials top indications, by phase
- Figure 29: Terminated clinical trials for sponsors, by phase
- Figure 30: Clinical trials for COVID-19, by status and sponsor type
- Figure 31: Clinical trials for COVID-19, by phase
- Figure 32: Clinical trials for COVID-19, by top industry sponsors
- Figure 33: Clinical trials for COVID-19, by top non-industry sponsors
- Figure 34 and 35: Clinical trials for COVID-19, by molecule type and phase
- Figure 36 and 37: Virtual trial components
